A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases
Open Access
- 23 October 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1257159
Abstract
There is an increasing interest in the pathophysiological role of the kynurenine pathway of tryptophan metabolism in the regulation of immune function and inflammation. We sought to address the link between this pathway and the presence rheumatic diseases (RD) by conducting a systematic review and meta-analysis of studies reporting the plasma or serum concentrations of tryptophan, kynurenine, and other relevant metabolites in RD patients and healthy controls. We searched electronic databases for relevant articles published between inception and the 30th of June 2023. Risk of bias and certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and the Grades of Recommendation, Assessment, Development and Evaluation Working Group system. In 24 studies selected for analysis, compared to controls, RD patients had significantly lower tryptophan (standard mean difference, SMD= -0.71, 95% CI -1.03 to -0.39, p2 = 93.6%, p2 = 93.2%, p2 = 92.9%, p2 = 87.7%, p2 = 88.1%, p<0.001; extremely low certainty). By contrast, there were non-significant between-group differences in kynurenic acid, 3-hydroxyanthranilic acid, kynurenic acid to kynurenine ratio, or quinolinic acid to kynurenine acid ratio. In meta-regression, the SMD of tryptophan, kynurenine, and kynurenine to tryptophan ratio were not associated with age, publication year, sample size, RD duration, C-reactive protein, or use of anti-rheumatic drugs and corticosteroids. In subgroup analysis, the SMD of tryptophan, kynurenine, and kynurenine to tryptophan ratio was significant across different types of RD, barring rheumatoid arthritis. Therefore, we have observed significant alterations in tryptophan, kynurenine, 3-hydroxykynurenine, and quinolinic acid concentrations in RD patients. Further research is warranted to determine whether these biomarkers can be useful for diagnosis and management in this patient group. (PROSPERO registration number: CRD CRD42023443718).Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD CRD42023443718.Keywords
This publication has 91 references indexed in Scilit:
- Nitric oxide synthases: regulation and functionEuropean Heart Journal, 2011
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?Arthritis Research & Therapy, 2009
- A Proposed Classification of the Immunological DiseasesPLOS Medicine, 2006
- Diagnostic Tests for Rheumatic Disease: Clinical Utility RevisitedSouthern Medical Journal, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Nitric oxide NO - biogeneration regulation and relevence to human diseasesFrontiers in Bioscience-Landmark, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Statistical Power AnalysisCurrent Directions in Psychological Science, 1992
- The actions of interferon and antiinflammatory agents on induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytesBiochemical and Biophysical Research Communications, 1987